Abstract CT051: Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL
Haneen Shalabi(Center for Cancer Research), Nirali N. Shah(National Institutes of Health), Steven L. Highfill(National Institutes of Health), Constance M. Yuan(National Cancer Institute), Terry J. Fry(University of Colorado Anschutz Medical Campus), Bonnie Yates(National Institutes of Health), Katherine Graap(National Institutes of Health), Maryalice Stetler‐Stevenson(National Cancer Institute), Shilpa Shahani(City of Hope), David F. Stroncek(Yale University), Haiying Qin(National Institutes of Health), Lauren Little(Rush University), Minh Tran(National Institutes of Health), Sandhya R. Panch(University of Washington), Hao‐Wei Wang(Fu Jen Catholic University), Leah Hoffman(Medical College of Wisconsin)
Cited by 8
Related Papers
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
|Genes & Development|2010|744
CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
|Nature Communications|2016|435
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
|Journal of Clinical Oncology|2020|422
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
|Nature Reviews Clinical Oncology|2022|324